Remarks

Applicants have amended claims 2 and 13-15, added claims 45-50 and canceled claims 4 and 22. With the entry of this amendment, claims 1-2, 6-21, 30, 38, and 40-50 are pending.

Rejections under 35 USC § 103

Applicants traverse the prior art rejections of record and assert that the claimed invention is non-obvious for the following reasons.

Ikesu et al. (USP5,208,141) discloses a compound having the following structural formula:



wherein X is a hydrogen atom or a substituent capable of slitting off upon reaction with an oxidation product of a color developing agent (halogen atom, alkoxy, aryloxy, heterocyclic oxy, acyloxy, sulfonyloxy, alkoxycarbonyloxy, aryloxycarbonyl, alkyloxalyloxy, alkoxyoxalyloxy, alkylthio, arylthio, heterocyclic thio, alkyloxythiocarbonylthio, acylamino, sulfonamide, nitrogero-containing heterocycle linked via a nitrogen atom, alkyloxycarbonylamino, aryloxycarbonylamino and carboxyl group).

However, in the sole compound actually disclosed in Ikesu et al., X is hydrogen atom, halogen, aryloxy, arylthio or nitrogen-containing heterocycle linked via a nitrogen atom, the carbon atom at the 3-position of the oxoimidazo[1,2-a]pyrimidine, which has N-containing 5-menbered ring, and X form a C-H bond, C-Hal (halogen) bond, C-O bond, C-S bond or C-N bond, and the 8-position of the oxoimidazo[1,2-a]pyrimidine is unsubstituted.

In addition, the use of the compound of Ikesu et al. is also for a silver halide color photographic light-sensitive material, which is a non-pharmaceutical use.

In contrast, the present invention relates to a compound characterized in that it has a substituent at the 1-position of oxopyrrolo[1,2-a]pyrimidine (corresponding to the 8-position of oxoilmidazo[1,2-a]pyrimidine), which has a 5-membered ring free of N, and a substituent that forms a C-C bond with the carbon atom at the 6-position of oxopyrrolo[1,2-a]pyrimidine (corresponding to the 3-position of oxoimidazo[1,2-a]pyrimidine). Thus, the compound of Ikesu et al. and the compound of the present invention are completely different in chemical structure and nothing in Ikesu or Abdalla would suggest the compounds of the present claims. In addition, the present invention relates to a pharmaceutical use, particularly the use as a GnRH antagonist, which is completely different from the use of the compound of Ikesu et al.

Abdalla et et al. (J. Heterocyclic Chemistry 24, 297, 1987) discloses a compound having the following structural formula:



Namely, Abdalla et al. merely disclose a compound wherein the 8-position of oxopyrrolo[1,2-a]pyrimidine is substituted by CN and the 6-position of oxopyrrolo[1,2a]pyrimidine is not substituted.

Moreover, the use of the compound of Abdalla et al. is an antimicrobial agent.

In contrast the present invention relates to a compound characterized in that has a substituent at the 6-position of oxopyrrolo[1,2-a]pyrimidine and the 8-position of oxopyrrolo[1,2-a]pyrimidine is unsubstituted. Therefore, the compound of Abdalla et al. and the compound of the present invention are completely different in chemical structure. In addition, the use of the compound of the present invention is a GnRH antagonist, which is completely different from the use of the compound of Abdalla et al.

As discussed above, the compounds of Ikesu et al. and Abdalla et al. and the compounds of the present invention are completely different in chemical structure and use.

Conclusion

Applicants submit that the present application is now in condition for allowance, and favorable reconsideration thereof is respectfully requested. If the Examiner believes that an interview would advance prosecution of the application, he is invited to contact the undersigned by telephone. If there are any unaccounted fees due in connection with the filing of this Amendment, please charge the fees to our Deposit Account No. 19-0741.

Respectfully submitted,

Date August 18, 2003
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

By _____

Matthew E. Mulkeen
Registration No. 44,250

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.